To include your compound in the COVID-19 Resource Center, submit it here.

Patiromer: Additional Phase IIb data

Relypsa reported additional data from the open-label, international Phase IIb AMETHYST-DN trial in 306 patients with hyperkalemia due to Type II diabetes and CKD who

Read the full 251 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE